Aditxt Subsidiary Pearsanta Launches Clinical Study for Blood-Based Endometriosis Diagnostic
Aditxt's subsidiary Pearsanta has begun enrolling patients in a clinical study for a novel blood-based endometriosis test that could provide earlier, non-invasive detection compared to current surgical methods.
Aditxt Inc. (NASDAQ: ADTX) announced that its subsidiary Pearsanta Inc. has initiated enrollment in a prospective clinical study evaluating the Mitomic Endometriosis Test (MET), a novel blood-based diagnostic for early detection of endometriosis. The study will compare MET's performance to laparoscopic diagnosis, the current gold standard, across up to 1,000 participants referred for surgery.
The first enrollment site, Dedicated to Women OB/GYN in Dover, Delaware, has begun recruiting patients for the clinical trial. Pearsanta President Chris Mitton stated that this milestone supports validation of a non-invasive diagnostic alternative that could enable earlier and more accurate detection of endometriosis. This development represents a significant advancement in women's health diagnostics, potentially transforming how endometriosis is identified and managed.
Endometriosis affects approximately 10% of women worldwide and currently requires invasive laparoscopic surgery for definitive diagnosis. The condition often goes undiagnosed for years due to the reluctance of patients and physicians to pursue surgical confirmation. A blood-based test could dramatically reduce diagnostic delays and improve patient outcomes through earlier intervention.
Aditxt operates as a social innovation platform advancing health innovations across multiple therapeutic areas. The company's current programs focus on autoimmunity, cancer and early disease detection, infectious diseases, and women's health. Additional information about Aditxt is available in the company's newsroom at https://ibn.fm/ADTX. The full press release detailing this clinical study initiation can be viewed at https://ibn.fm/WiIhM.
The clinical validation of MET represents an important step toward addressing the significant diagnostic challenges in endometriosis care. If successful, this blood-based test could provide physicians with a valuable tool for early detection, potentially reducing the average diagnostic delay of 7-10 years that many endometriosis patients currently experience. The study's large participant pool of up to 1,000 individuals will provide robust data on the test's accuracy and clinical utility compared to the existing surgical standard.